



PRESS RELEASE  
FOR IMMEDIATE DISTRIBUTION  
September 16, 2015  
Maastricht, The Netherlands

## Acacia Designs acquires T4Analytics

**Acacia Designs BV has acquired substantially all the assets of T4Analytics LLC, a US-based medical device company in the field of anesthesia monitoring. The acquisition strengthens Acacia's IP-portfolio and accelerates the entry into the US market.**

T4Analytics LLC ("T4") is a US medical device company founded in 2011. T4 has developed novel, patent pending solutions for monitoring patients undergoing anesthesia to determine when it is safe to wake up the patient and allow spontaneous breathing following surgery. T4 has collaborated with Mayo Clinic to develop the products and holds an IP license.

T4's solutions are intended specifically to enable improved patient safety following the administration of paralytic drugs, also known as neuromuscular blocking agents (NMBAs). It is essential to monitor patients who receive NMBAs to ensure the correct NMBA dose and to determine when patients can be safely transferred from the operating room to the postoperative care unit. Objective monitoring of the effects of NMBAs has also shown to reduce the incidence of postoperative pulmonary complications as well as improve patient satisfaction and reduce hospital length of stay.

Philip Siberg, CEO of Acacia comments: "This is a major milestone for Acacia, for the anesthesia community and for the many patients who deserve better monitoring when paralytic drugs are used. The acquisition of T4 strengthens our leading product and IP portfolio, and it enables us to accelerate the entry into the important US market."

Michael E Turner, Managing Director of T4Analytics, comments, "T4 is pleased to see its IP and technology united with that of Acacia Designs, and to be part of the world-class team that Acacia has assembled. We believe that Acacia is on track to develop the first advanced neuromuscular monitor practical for standard use in operating rooms and ICUs throughout the world. That will save countless lives, and T4 is very proud to be a part of that effort."

Paralytic drugs are used in over 70 million patients per year. Research has shown that inadequate monitoring of these patients can lead to postoperative respiratory complications, the second most common complication following surgery. In a recent clinical study of 100 patients, implementation of quantitative (objective) neuromuscular monitoring was shown to reduce the incidence of postoperative complications by 52%, while completely eliminating the need for emergent tracheal re-intubation. (Todd MM, Anesth Analg 2014). Other recent studies have documented that monitoring may also reduce the potential for awareness or consciousness during surgery, also known as intraoperative recall (Thomsen JL, 2015).

For more information, please contact:

Philip Siberg, CEO

Acacia Designs BV.

[philip@acaciadesigns.eu](mailto:philip@acaciadesigns.eu), or +46 70 7906734

### About Acacia Designs BV:

Acacia is a clinical intellectual property company developing high-quality medical monitoring devices that are based on physiologic principles. The mission is to improve patient outcomes and safety by developing solutions that set new clinical standards of patient monitoring during surgery and in the intensive care unit. Acacia Designs was founded and is run by internationally recognized, experienced leaders in the field of anesthesia and medical device development. Acacia is currently funded by US- and Sweden-based investors. Read more at [www.acaciadesigns.eu](http://www.acaciadesigns.eu)